Search | Clinical Trials Finder

Conditions: Magnetic Resonance Imaging
Interventions: Gadoterate (Dotarem/Clariscan), Gadobutrol (Gadavist/Gadovist, BAY86-4875); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: Chicago, Illinois • New York, New York • Hershey, Pennsylvania + 1 more

Conditions: Magnetic Resonance Imaging
Interventions: Gadobutrol (Gadavist, BAY86-4875); Drug
Lead sponsor: Bayer; Industry
Eligibility: Up to 2 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Savannah, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Urinary Bladder Neoplasms
Interventions: Magnetic Resonance Imaging, Gadobutrol intravesical administration (4mM), Ferumoxytol intravesical administration (5 mM); Diagnostic Test · Drug
Lead sponsor: Jodi Maranchie; Other
Eligibility: 18 Years to 90 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Gynecologic Cancer
Interventions: Gadobutrol, MRI; Drug · Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: Montvale, New Jersey • New York, New York • Uniondale, New York

Conditions: Leptomeningeal Disease
Interventions: MRI Scan, VUEWAY, Gadavist; Procedure · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Central Nervous System Diseases
Interventions: Gadobutrol (Gadavist, Gadovist, BAY86-4875); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 21
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 17 more

Conditions: Coronary Atherosclerosis
Interventions: Cardiac MRI, Contrast, Beta blocker; Device · Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Contrast Enhancement in Magnetic Resonance Imaging, Non-central Nervous System Pathology
Interventions: Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine, Gadoteridol; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Birmingham, Alabama • Indian Wells, California • Orange, California + 6 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Wayne State University; Other
Eligibility: 20 Years to 59 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Breast Cancer, Diagnostic Imaging
Interventions: Gadobutrol (Gadavist, Gadovist, BAY86-4875); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 7
States / cities: La Jolla, California • Los Angeles, California • Newport Beach, California + 4 more

Conditions: Breast Diseases
Interventions: Gadoterate meglumine, Gadobutrol; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Breast Cancer
Interventions: Gadobutrol (Gadavist, Gadovist, BAY86-4875); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 9
States / cities: Tucson, Arizona • Oakland, California • Englewood, Colorado + 6 more

Conditions: Cancer
Interventions: Bone scan, 99mTc-methyl diphosphonate, Positron Emission Tomography (PET) scan, 18F-Fludeoxyglucose (18F-FDG), Computed Tomography (CT) scan, 18F-Sodium Fluoride (18F-NaF), Whole Body Magnetic Resonance Imaging (WB-MRI) scan, Gadopentetate dimeglumine, Gadofosveset, Gadobutrol; Procedure · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 1
States / cities: Stanford, California

Conditions: Intracranial Atherosclerosis
Interventions: Feraheme; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Contrast Enhancement in Magnetic Resonance Imaging
Interventions: Gadobutrol (Gadavist/Gadovist, BAY86-4875); Drug
Lead sponsor: Bayer; Industry
Eligibility: Not listed
Enrollment: 1,602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Motor Function, Cognitive Function, Contrast Media
Interventions: Motor Tests, Cognitive Tests, Unenhanced-MRI of the brain, Gadolinium Measurements, Gadoxetate disodium, Gadobenate dimeglumine, Gadodiamide, Gadoterate meglumine, Gadobutrol, Gadoteridol; Procedure · Drug
Lead sponsor: Guerbet; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 2,076 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 16
States / cities: Scottsdale, Arizona • New Haven, Connecticut • Chicago, Illinois + 11 more

Conditions: Primary Brain Tumor
Interventions: Dotarem®, Gadovist®/Gadavist®; Drug
Lead sponsor: Guerbet; Industry
Eligibility: 18 Years and older
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 14
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 11 more

Conditions: Prostate Adenocarcinoma
Interventions: C-11 choline PET tracer, Gadobutrol, PET/MR scanner; Drug · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Brain Tumor Adult
Interventions: Hyperpolarized 13C-Pyruvate, Gadolinium; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Central Nervous System Pathology
Interventions: Gadoquatrane (BAY1747846), Gadobutrol (Gadovist/Gadavist); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 3
States / cities: Chicago, Illinois • Iowa City, Iowa • Hershey, Pennsylvania

Conditions: Central Nervous System Neoplasms
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Lesion in Body Region
Interventions: gadopiclenol, Gadobutrol 1 MMOLE/ML Intravenous Solution; Drug
Lead sponsor: Guerbet; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 7
States / cities: Birmingham, Alabama • Farmington, Connecticut • Chicago, Illinois + 4 more

Conditions: Known or Highly Suspected Central Nervous System (CNS) Lesion, Known or Highly Suspected Body (Excluding CNS) Lesion
Interventions: Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL, MRI Scan, Gadobutrol; Drug · Diagnostic Test
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Rochester, Minnesota • The Woodlands, Texas

Conditions: Glioblastoma
Interventions: Positron Emission Tomography, Computed Tomography, Multiparametric Magnetic Resonance Imaging Scan, Fludeoxyglucose F-18, fluorine F 18 fluorodopa; Procedure · Radiation
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Charlottesville, Virginia

Search by objective public record fields.

Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose

Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)

Virtual Histology of the Bladder Wall for Bladder Cancer Staging

Novel Imaging Technique to Assess Gynecologic Cancer

Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease

Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging

Coronary Atherosclerosis T1-Weighted Characterization (CATCH)

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)

Imaging Multiple Sclerosis Lesions Using Magnevist and Gadavist

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI

Dotarem vs Gadobutrol Contrast for Breast MRI

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

Predicting Stroke Risk in ICAD With Novel MRI

A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors

Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI

Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)

Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions

Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients

Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)

A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients

FDG and FDOPA PET Demonstration of Functional Brain Abnormalities